Patents by Inventor Floyd R. Sallee

Floyd R. Sallee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment methods employing histamine Hreceptor antagonists, including betahistine
    Patent number: 8242148
    Abstract: Methods of treating depression, binge eating disorder, narcolepsy, excessive daytime sleepiness, substance use disorders, and Prader Willi syndrome, disorders characterized at least in part by hypocortisolemia and decreased activity of the hypothalamic-pituitary-adrenal (HPA) axis, and disorders related to disturbances in circadian rhythm, comprising the step of administering an effective amount of a histamine type 3 (H3) receptor antagonist, such as betahistine or its pharmaceutically acceptable salts, or its metabolites to an individual.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: August 14, 2012
    Inventors: Erik B. Nelson, Floyd R. Sallee
  • Treatment Methods Employing Histamine H3 Receptor Antagonists, Including Betahistine
    Publication number: 20120115914
    Abstract: Methods of treating depression, binge eating disorder, narcolepsy, excessive daytime sleepiness, substance use disorders, and Prader Willi syndrome, disorders characterized at least in part by hypocortisolemia and decreased activity of the hypothalamic-pituitary-adrenal (HPA) axis, and disorders related to disturbances in circadian rhythm, comprising the step of administering an effective amount of a histamine type 3 (H3) receptor antagonist, such as betahistine or its pharmaceutically acceptable salts, or its metabolites to an individual.
    Type: Application
    Filed: January 11, 2012
    Publication date: May 10, 2012
    Inventors: Erik B. Nelson, Floyd R. Sallee
  • Treatment methods employing histamine Hreceptor antagonists, including betahistine
    Patent number: 8119668
    Abstract: Methods of treating depression, binge eating disorder, narcolepsy, excessive daytime sleepiness, substance use disorders, and Prader Willi syndrome, disorders characterized at least in part by hypocortisolemia and decreased activity of the hypothalamic-pituitary-adrenal (HPA) axis, and disorders related to disturbances in circadian rhythm, comprising the step of administering an effective amount of a histamine type 3 (Bb) receptor antagonist, such as betahistine or its pharmaceutically acceptable salts, or its metabolites to an individual.
    Type: Grant
    Filed: December 26, 2006
    Date of Patent: February 21, 2012
    Inventors: Erik B. Nelson, Floyd R. Sallee
  • Treatment Methods Employing Histamine H3 Receptor Antagonists, Including Betahistine
    Publication number: 20090298892
    Abstract: Methods of treating depression, binge eating disorder, narcolepsy, excessive daytime sleepiness, substance use disorders, and Prader Willi syndrome, disorders characterized at least in part by hypocortisolemia and decreased activity of the hypothalamic-pituitary-adrenal (HPA) axis, and disorders related to disturbances in circadian rhythm, comprising the step of administering an effective amount of a histamine type 3 (Bb) receptor antagonist, such as betahistine or its pharmaceutically acceptable salts, or its metabolites to an individual.
    Type: Application
    Filed: December 26, 2006
    Publication date: December 3, 2009
    Inventors: Erik B. Nelson, Floyd R. Sallee